U.S., Sept. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07183709) titled 'Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults' on Sept. 18.
Brief Summary: This Phase 1 clinical trial will evaluate the safety, reactogenicity, and immunogenicity of PepGNP-COVID19, a synthetic nanoparticle-based, T cell-priming peptide vaccine against SARS-CoV-2, when administered as a booster dose in healthy adults. PepGNP-COVID19 is designed to induce broad and durable T cell-mediated immune responses by delivering conserved SARS-CoV-2 peptides covalently bound to carbohydrate-coated gold nanoparticles, with the goal of enhancing tissue-resident cytotoxic T lymphocytes in the respiratory tract and reducing...